Janus kinase inhibitors: between prescription authorization and reimbursability.
Reumatismo
; 75(4)2023 Dec 19.
Article
en En
| MEDLINE
| ID: mdl-38115771
ABSTRACT
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Reumatología
/
Inhibidores de las Cinasas Janus
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article